Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.
Researchers at Vanderbilt University School of Medicine have uncovered a link between epidermal growth factor receptor (EGFR) signaling and the inflammatory response to bacterial infection in the gastrointestinal tract.
Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
Understanding how signaling molecules are transported within and out of the cell may help to uncover the causes of certain cancers.
Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.
Berberine, an herbal remedy for diarrhea and intestinal parasites, may be useful in colon cancer therapy.